Literature DB >> 28059928

Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months.

Zachary R Stoecker1, Wales T George, Jeffrey B O'Brien, Jon Jancik, Eduardo Colon, Joseph J Rasimas.   

Abstract

The aim of this study was to determine whether the incidence of pneumonia in patients taking clozapine was more frequent compared with those taking risperidone or no atypical antipsychotics at all before admission to a tertiary care medical center. This was a retrospective, case-matched study of 465 general medicine patients over a 25 month period from 1 July 2010 to 31 July 2012. Detailed electronic medical records were analyzed to explore the association between the use of two atypical antipsychotics and incidence of pneumonia. Of the 155 patients in the clozapine group, 54 (34.8%) had documented pneumonia compared with 22 (14.2%) in the risperidone group and 18 (11.6%) in the general population group. Clozapine, when compared with the untreated general population, was associated with an increased risk of pneumonia (odds ratio=4.07; 95% confidence interval=2.25-7.36). There was, however, no significant increase in the risk of pneumonia associated with the use of risperidone (odds ratio=1.26; 95% confidence interval=0.65-2.45). Clozapine use is associated with increased risk of pneumonia that may be related to immunologic factors or side effects of sedation and drooling that make aspiration more likely, although causative mechanisms require further investigation. These findings suggest that providers should use added caution in choosing candidates for clozapine therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28059928     DOI: 10.1097/YIC.0000000000000162

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  7 in total

1.  Covert dysphagia and recurrent pneumonia related to antipsychotic treatment.

Authors:  Jonathan T Stewart
Journal:  J Psychiatry Neurosci       Date:  2018-03       Impact factor: 6.186

2.  Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics.

Authors:  Jose de Leon; Emilio J Sanz; G Niklas Norén; Carlos De Las Cuevas
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

3.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

4.  Risk of pleural empyema in patients with schizophrenia: a nationwide propensity-matched cohort study in Taiwan.

Authors:  Chuen-Ming Shih; Fung-Chang Sung; Te-Chun Shen; Chia-Hung Chen; Yu-Jhen Huang; Cheng-Li Lin; Ting-Chang Chang; Chih-Yen Tu; Te-Chun Hsia; Wu-Huei Hsu
Journal:  BMJ Open       Date:  2018-07-06       Impact factor: 2.692

5.  COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine.

Authors:  Risha Govind; Daniela Fonseca de Freitas; Megan Pritchard; Mizanur Khondoker; James T Teo; Robert Stewart; Richard D Hayes; James H MacCabe
Journal:  Eur Neuropsychopharmacol       Date:  2022-01-24       Impact factor: 5.415

6.  Clozapine treatment and risk of severe COVID-19 infection.

Authors:  Anna Ohlis; Alma Sörberg Wallin; Anna Sarafis; Hugo Sjöqvist; James H MacCabe; Johan Ahlen; Christina Dalman
Journal:  Acta Psychiatr Scand       Date:  2021-10-29       Impact factor: 7.734

7.  Management of clozapine treatment during the COVID-19 pandemic.

Authors:  Siobhan Gee; Fiona Gaughran; James MacCabe; Sukhi Shergill; Eromona Whiskey; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.